Clinical Trial

A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
NTQ5082 capsule is a small molecule CFB factor inhibitor. This study is a multicenter, randomized, open label phase II clinical trial aimed at evaluating the efficacy, safety, and PK/PD characteristics of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-01; most recent amendment 2025-09-19.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-10
Trial Details
NCT Number NCT06764303
Lead Sponsor Nanjing Chia-tai Tianqing Pharmaceutical
Conditions Paroxysmal Nocturnal Hemoglobinuria
Enrollment 24 participants
Start Date 2025-01-23
Primary Completion 2025-07-08 (estimated)
Study Completion 2027-07-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-23